CEORT, Paradigm Health launch PACT Collective, expand clinical trial access and diversity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CEO Roundtable on Cancer and Paradigm Health Inc. announced a strategic partnership to launch the Partnership for Access, Collaboration, and Trust Collective. This pioneering initiative aims to break down barriers and create equitable access to oncology clinical trials, particularly for African American, Hispanic, and other underrepresented patient groups.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login